Laura Cerchia
Overview
Explore the profile of Laura Cerchia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
1775
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Venegoni C, Tortorella S, Caliendo A, Locatelli I, Coste A, Locatelli E, et al.
Adv Healthc Mater
. 2025 Feb;
:e2403314.
PMID: 39935083
The limitations of current diagnostic imaging techniques and therapies for bladder cancer are associated with and responsible for the recurrence and progression of residual disease, with an impact on social...
2.
Ferrara Y, Latino D, Costagliola di Polidoro A, Oliver A, Sarnella A, Caprio M, et al.
Cell Commun Signal
. 2025 Feb;
23(1):74.
PMID: 39930439
Background: Current conventional treatment regimens for head and neck squamous cell carcinoma (HNSCC), are poorly effective because of the emergence of resistance mechanisms. Many studies have reported how the tumor...
3.
Veglia Tranchese R, Battista S, Cerchia L, Fedele M
Biomolecules
. 2024 Nov;
14(11).
PMID: 39595619
Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, has emerged as a critical pathway in cancer biology. This review delves into the epigenetic mechanisms that modulate...
4.
Ibarra L, Camorani S, Agnello L, Pedone E, Pirone L, Chesta C, et al.
Pharmaceutics
. 2024 Oct;
16(10).
PMID: 39458677
In the original publication [...].
5.
Camorani S, Caliendo A, Morrone E, Agnello L, Martini M, Cantile M, et al.
J Exp Clin Cancer Res
. 2024 Aug;
43(1):243.
PMID: 39175098
No abstract available.
6.
Camorani S, Caliendo A, Morrone E, Agnello L, Martini M, Cantile M, et al.
J Exp Clin Cancer Res
. 2024 Mar;
43(1):92.
PMID: 38532439
Background: Based on the established role of cancer-stroma cross-talk in tumor growth, progression and chemoresistance, targeting interactions between tumor cells and their stroma provides new therapeutic approaches. Dual-targeted nanotherapeutics selectively...
7.
Fedele M, Cerchia L, Battista S
Cells
. 2024 Feb;
13(4.
PMID: 38391963
The classification of tumors into subtypes, characterized by phenotypes determined by specific differentiation pathways, aids diagnosis and directs therapy towards targeted approaches. However, with the advent and explosion of next-generation...
8.
Agnello L, dArgenio A, Caliendo A, Nilo R, Zannetti A, Fedele M, et al.
Cells
. 2023 Jul;
12(13).
PMID: 37443843
Triple-negative breast cancer (TNBC) is among the most aggressive breast cancer subtypes. Despite being initially responsive to chemotherapy, patients develop drug-resistant and metastatic tumors. Tissue inhibitor of metalloproteinases-1 (TIMP-1) is...
9.
Luca S, Franco R, Napolitano A, Soria V, Ronchi A, Marino F, et al.
Cancers (Basel)
. 2023 Apr;
15(7).
PMID: 37046851
Non-small cell lung cancer (NSCLC), the leading cause of cancer death worldwide, is still an unmet medical problem due to the lack of both effective therapies against advanced stages and...
10.
Agnello L, dArgenio A, Nilo R, Fedele M, Camorani S, Cerchia L
Cancers (Basel)
. 2023 Apr;
15(7).
PMID: 37046670
The immune system (IS) may play a crucial role in preventing tumor development and progression, leading, over the last years, to the development of effective cancer immunotherapies. Nevertheless, immune evasion,...